Patents by Inventor Jolie Bastian

Jolie Bastian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS
    Publication number: 20070072869
    Abstract: Compounds of formula (I) in which R, R1, R2, n and X1 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Application
    Filed: July 11, 2006
    Publication date: March 29, 2007
    Inventors: Michael Wiley, Daniel Sall, Christopher Murray, Stephen Young, Jolie Bastian
  • BETA 3 ADRENERGIC AGONISTS
    Publication number: 20060142329
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
    Type: Application
    Filed: February 17, 2006
    Publication date: June 29, 2006
    Inventors: Jolie Bastian, Gerd Ruehter, Daniel Sall, Theo Schotten
  • BETA 3 ADRENERGIC AGONISTS
    Publication number: 20060142328
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
    Type: Application
    Filed: February 17, 2006
    Publication date: June 29, 2006
    Inventors: Jolie Bastian, Gerd Ruehter, Daniel Sall, Theo Schotten
  • BETA 3 ADRENERGIC AGONISTS
    Publication number: 20060142327
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (1) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
    Type: Application
    Filed: February 17, 2006
    Publication date: June 29, 2006
    Inventors: Jolie Bastian, Gerd Ruehter, Daniel Sall, Theo Schotten
  • 3-Substituted oxindole beta3 agonists
    Publication number: 20050159473
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: March 16, 2005
    Publication date: July 21, 2005
    Inventors: Daniel Sall, Jolie Bastian, Cynthia Jesudason, Don Finley, Freddie Stevens, Vincent Rocco, Patrick Spinazze, John He, John Werner, William Trankle, Andrew Ratz, Theo Schotten, Gerd Reuhter
  • Beta 3 adrenergic agonists
    Publication number: 20050080110
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: August 6, 2002
    Publication date: April 14, 2005
    Inventors: Daniel Sall, Jolie Bastian, Rushad Karanjawala, Cynthia Jesudason, Theo Schotten, Britta Evers, Gerd Reuhter, Don Finley, Freddie Stevens, Vincent Rocco, Patrick Spinazze, John He, John Werner, William Trankle, Andrew Ratz
  • 3-substituted oxindole beta3 agonists
    Publication number: 20050020617
    Abstract: The present invention relates to a ?3 adrenegc receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetess and/or obesity.
    Type: Application
    Filed: November 12, 2002
    Publication date: January 27, 2005
    Inventors: Jolie Bastian, Gerd Ruehter, Daniel Sall, Theo Schotten
  • Beta 3 adrenergic agonists
    Publication number: 20050020618
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity.
    Type: Application
    Filed: November 12, 2002
    Publication date: January 27, 2005
    Inventors: Jolie Bastian, Gerd Ruehter, Daniel Sall, Theo Schotten
  • Antithrombotic agents
    Patent number: 6541499
    Abstract: The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: April 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Jolie A Bastian, Nickolay Y Chirgadze, Michael L Denney, Matthew J Fisher, Robert J Foglesong, Richard W Harper, Mary G Johnson, Valentine J Klimkowski, Ho-Shen Lin, Michael P Lynch, Jefferson R McCowan, Shawn C Miller, Jeffrey T Mullaney, Michael E Richett, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Jennifer M Tinsley, Michael R Wiley, Minsheng Zhang
  • Antithrombotic agents
    Patent number: 6350774
    Abstract: This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: February 26, 2002
    Assignee: Eli Lilly And Company
    Inventors: Nicholas J Bach, Jolie A. Bastian, Nickolay Y Chirgadze, Michael L Denney, Robert J. Foglesong, Richard W Harper, Mary G Johnson, Ho-Shen Lin, Michael P Lynch, Jefferson R McCowan, Alan D Palkowitz, Daniel J Sall, Gerald F Smith, Kumiko Takeuchi, Minsheng Zhang